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Abstract
Crizotinib is a multi-targeted tyrosine kinase inhibitor (TKI) with activity against mesenchymal-epithelial transition
factor (MET) and anaplastic lymphoma kinase (ALK). However, the concomitant oncogenic drivers may affect the
sensitivity of crizotinib. Herein, we present a 69-year-old never-smoker Chinese male with advanced lung
adenocarcinoma harboring concomitant spectrin beta non-erythrocytic 1 (SPTBN1)-ALK fusion, c-Met overexpression,
and human epidermal growth factor receptor-2 (HER-2) amplification with inherent resistance to crizotinib,
chemotherapy, and radiotherapy. Although the patient received timely and comprehensive treatment, the overall
survival was only 8 months. Therefore, c-Met overexpression, HER-2 gene amplification, and SPTBN1-ALK gene fusion
can coexist in lung adenocarcinoma and may become a potential biomarker of cancer refractory to crizotinib,
chemotherapy, and radiotherapy as well as of a relatively poor prognosis. In addition, the novel SPTBN1-ALK fusion
gene may become a potential target for anti-tumor therapy.
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To the editor
Crizotinib is a multi-targeted tyrosine kinase inhibitor
(TKI) with activity against mesenchymal-epithelial transi-
tion factor (MET) and anaplastic lymphoma kinase (ALK)
[1]. Driver oncogenes are conventionally considered
mutually exclusive [2]. Here, we describe a rare case of lung
adenocarcinoma harboring concomitant spectrin beta non-
erythrocytic 1 (SPTBN1)-ALK fusion, c-Met overexpres-
sion, and human epidermal growth factor receptor-2 (HER-
2) amplification with inherent resistance to crizotinib,
chemotherapy, and radiotherapy.
In July 2015, a 69-year-old never-smoker man, whose
brother died of lung cancer, experiencing pain in his low
back and left lower extremity, underwent a total-body
positron emission tomography-computed tomography
(PET/CT) scan which showed a lung tumor and bone
metastases (Fig. 1d–f ). Then, a CT-guided percutaneous
lung biopsy was performed (Fig. 1a), and a diagnosis of
advanced lung adenocarcinoma was made. Based on the
immunohistochemistry analysis, the tumor cells were
negative for ALK (Fig. 1c) but extremely positive for c-
Met (Fig. 1b). In addition, epidermal growth factor
receptor (EGFR) mutation and repressor of silencing 1
(ROS-1) fusion detections revealed negative results.
The patient initially received gemcitabine plus neda-
platin for one cycle in July 2015. Subsequent treatment
included palliative radiation therapy to the left ilium.
Additionally, the patient was treated with crizotinib
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based on c-Met overexpression. However, grade 3
thrombocytopenia occurred after chemotherapy, and he
recovered with recombinant human thrombopoietin. Al-
though the symptoms decreased, first restaging CT scans
(September 2, 2015) showed marked worsening disease
(Additional file 1: Figure S1a).
Then, the patient received two cycles of bevacizumab-
based chemotherapy with pemetrexed, cisplatin, and
bevacizumab from September to October in 2015.
Additionally, he received local radiotherapy at the lum-
bar metastases. However, lumbar MRI and CT scan of
the chest and abdomen (October 2015) showed progres-
sive disease (Additional file 1: Figure S1b).
Given the patient’s reduced performance status, re-
duced paclitaxel liposome plus nedaplatin was adminis-
tered (October 27, 2015). Subsequent treatments
included iAPA DC-CIK and chest radiotherapy. How-
ever, the patient demonstrated evidence of progressive
disease again in December 2015 (Additional file 1: Figure
S1c). To re-evaluate the molecular characteristics, DNA
extracted from the original biopsy was used for DNA se-
quencing with next-generation sequencing on December
2015. Interestingly, the patient had HER-2 amplification
and a novel ALK rearrangement, namely SPTBN1-ALK
fusion, which was created by an insertion between two
breakpoints in exons 1 to 6 of the SPTBN1 gene and
exons 20 to 29 of the ALK gene (Fig. 2). Given the pa-
tient’s performance interfered with starting chemother-
apy, he was treated with whole-brain irradiation therapy.
However, the patient’s performance status continuously
deteriorated. On January 4, 2016, the patient died of
brain and lung metastases. The patient’s overall survival
was only 8 months.
The SPTBN1-ALK fusion gene was first identified in
colorectal cancer, which was formed by the fusion of
exon 7 of the SPTBN1 gene with exon 20 of the ALK
gene [3]. In this case, we first identified a novel
SPTBN1-ALK fusion in lung cancer. The frequency of c-
Met overexpression is 31.9 % in NSCLC, and it poten-
tially causes intrinsic resistance to EGFR-TKIs without
causing resistance to crizotinib [4]. Nonetheless, the
present patient gained inherent crizotinib resistance des-
pite harboring both c-Met overexpression and the
SPTBN1-ALK fusion gene. HER-2 is noted in 10 to 20 %
Fig. 1 Lung biopsy specimens and total-body PET/CT scan before treatment. Hematoxylin and eosin (H & E) staining (magnification ×200, a), IHC
of c-Met (magnification ×200, b), and ALK (magnification ×100, c) of a diagnostic biopsy specimen. Total-body PET/CT showed a 5.1 × 3.7 cm-sized
tumor in the right upper lobe (d) with the second lumbar and left ilium metastases (arrowheads, e, f)
Fig. 2 Hypothetical structure of SPTBN1-ALK fusion gene. SPTBN1-ALK fusion gene was formed by placing SPTBN1 exons 1–6 upstream of ALK exons
20–29, which were separated by small genomic shards
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of NSCLC patients [5] and confers relative resistance to
conventional chemotherapy [6]. The novel ALK re-
arrangement and interactive crosstalk between Met and
HER2 may have been responsible for the failed response
to crizotinib treatment. In this context, inhibition of
ALK, Met, and Her-2 was required for efficient inhib-
ition of tumor growth.
To the best of our knowledge, this is the first case of
lung cancer with a novel SPTBN1-ALK fusion gene, which
may become a potential target for anti-tumor therapy.
This interesting case demonstrates that c-Met overexpres-
sion, HER-2 gene amplification, and SPTBN1-ALK gene
fusion can coexist in lung adenocarcinoma, and their
combination might be a biomarker for resistance to crizo-
tinib, traditional chemotherapy, and radiotherapy as well
as for a relatively poor prognosis. Further evidence is re-
quired to validate these preliminary data.
Additional file
Additional file 1: Figure S1. Multiple metastases after three treatment
approaches (a) CT scans of the chest and abdomen showed mediastinal
lymph nodes metastases (left, arrowhead), a soft tissue tumor located at the
axillary segment of the right sixth rib with bone destruction (middle,
arrowhead) and left adrenal metastasis (right, arrowhead) following the
first-line treatment. (b) After the second-line treatment, CT scans of the chest
and abdomen showed a soft tissue tumor at the right scapula with bone
destruction (left, arrowhead) and bilateral adrenal metastases (right, arrowheads).
Lumbar MRI showed the third lumbar metastasis (middle, arrowhead). (c) After
the third-line treatment, chest CT scans showed multiple bilateral pulmonary
nodules and axillary lymph nodes metastases (upper, arrowheads) and brain
MRI showed multiple brain metastases (lower, arrowheads). (TIF 13959 kb)
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